Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy
Cardiology Research and Practice · 23.08.2022 · 2022 · 1-7
DOI: 10.1155/2022/1638209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Research and Practice, erschienen am 23.08.2022. Verfasst von Yu Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Science and Technology Project of Tian Jin city, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI). However, to the best of our knowledge, no studies have investigated the potential effect of PCSK9 inhibitors on the prevalence of CI-AKI after percutaneous coronary intervention (PCI). This study aimed to determine whether PCSK9 inhibitors are associated with the prevalence of CI-AKI. The medical records of 309 (mean age, 63.35 years; 71.84% male) patients with acute myocardial infarction who underwent PCI at our institution were retrospectively analyzed. Overall, 149 and 160 patients were assigned to the evolocumab and control groups, respectively. Serum creatinine levels were examined preoperatively and 24–72 h postoperatively and compared between groups. Data were grouped according to the occurrence of CI-AKI, and a univariate analysis was conducted to exclude suspected influencing factors that led to CI-AKI occurrence. After adjusting for confounding factors, a logistic regression analysis was performed to assess the association between evolocumab administration (independent variable) and CI-AKI occurrence (dependent variable). The prevalence of CI-AKI was significantly lower in the evolocumab group (6.7%) than in the control group (20.0%; p < 0.01 ).We further evaluated the correlation between exposure factor and outcome. The relative risk(RR) between the use of evolocumab and the occurrence of CI-AKI was 0.34(95% CI 0.17-0.66,p
Autor:innen und Institutionen
- Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222, China.
- Tianjin Institute of Cardiovascular Diseases, Tianjin Chest Hospital, Tianjin 300222, China.
- Tianjin Medical University, Tianjin Chest Hospital, Tianjin 300222, China.
- Department of Cardiology, Clinical School of Thoracic, Tianjin Medical University, Jinnan, Tianjin 300222, China.
ORCID-Profile: Yu Ma, Lei Zha, Qi Zhang, Lu Cao, Ru Zhao, Jing Ma, Kai Hou, Yue Pan, Hongliang Cong, Ximing Li
Förderung
- Health Science and Technology Project of Tian Jin city
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Ma, Y., Zha, L., Zhang, Q., Cao, L., Zhao, R., Ma, J., Hou, K., Pan, Y., Cong, H., & Li, X. (2022). Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy. Cardiology Research and Practice, 2022, 1-7. https://doi.org/10.1155/2022/1638209
Vancouver
Ma Y, Zha L, Zhang Q, Cao L, Zhao R, Ma J, et al. Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy. Cardiology Research and Practice. 2022;2022:1-7. doi:10.1155/2022/1638209
BibTeX
@article{Ma2022,
author = {Ma, Yu and Zha, Lei and Zhang, Qi and Cao, Lu and Zhao, Ru and Ma, Jing and Hou, Kai and Pan, Yue and Cong, Hongliang and Li, Ximing},
title = {Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy},
journal = {Cardiology Research and Practice},
year = {2022},
volume = {2022},
pages = {1--7},
doi = {10.1155/2022/1638209}
}
EUVIMED